Monitor the integration of the four Heron products and their revenue contribution in upcoming quarters. The loan's amortization schedule and potential adjustment trigger (TTM Net Rezzayo Revenues >= $95M by Sep 2029) will be key credit metrics to track.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $5.47entry
- T+1 · 7d ago −1.83%α −1.46% · $5.37
- T+5 · 20h ago −11.88%α −10.19% · $4.82
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix entered into a loan agreement with BioPharma Credit for up to $50M in term loans to fund the acquisition of four commercial-stage products (Cinvanti, Zynrelef, Aponvie, Sustol) from Heron Therapeutics. The transaction includes a $145M cash component plus 14.58M shares of CorMedix common stock, with the loan secured by substantially all assets. The combined financing and acquisition significantly increases CorMedix's leverage and adds four marketed products to its portfolio.
Key Financial Metrics
Key Facts
- Loan agreement for up to $50M in term loans (Tranche A and Tranche B) from BioPharma Credit lenders
- Proceeds used to fund acquisition of Heron Therapeutics products: Cinvanti, Zynrelef, Aponvie, Sustol
- Asset purchase agreement with Heron: $145M base cash consideration plus 14,583,333 shares of CorMedix common stock
- Loan interest rate is Term SOFR plus 5.75% per annum, with quarterly payments starting ~3 years after closing
- Loan matures on Term Loan Maturity Date, with optional prepayment subject to make-whole and prepayment premium
- Loan secured by substantially all assets of CorMedix and its subsidiaries
- Heron acquisition also includes potential royalty and earn-out payments on net sales of acquired products
- CorMedix market cap is $407M; loan size represents ~12.3% of market cap
Financial Impact
Up to $50M in new debt financing; $145M cash plus 14.58M shares (~$59M at $4.05/share) in acquisition consideration; total deal value approximately $204M plus potential royalties
Risk Factors
- Increased leverage with up to $50M in secured debt
- Integration risk from acquiring multiple commercial-stage products from Heron
- Potential dilution from 14.58M shares issued to Heron (approximately 26% of current shares outstanding based on $407M market cap)
- Loan contains prepayment penalties and make-whole provisions that increase cost of early refinancing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-117213 |
| Document: ea031142301ex2-1.htm | 0001213900-26-117213 |
Track record
21 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Viewing Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers